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Glycogen storage disease type 1b (GSD1b) is an inherited metabolic defect of glycogenolysis and gluconeogenesis
due to mutations of the SLC37A4 gene and to defective transport of glucose-6-phosphate. The clinical presentation
of GSD1b is characterized by hepatomegaly, failure to thrive, fasting hypoglycemia, and dyslipidemia. Patients
affected by GSD1b also show neutropenia and/or neutrophil dysfunction that cause increased susceptibility to
recurrent bacterial infections. GSD1b patients are also at risk for inflammatory bowel disease. Occasional reports
suggesting an increased risk of autoimmune disorders in GSD1b patients, have been published. These complications
affect the clinical outcome of the patients. Here we describe the occurrence of autoimmune endocrine disorders
including thyroiditis and growth hormone deficiency, in a patient affected by GSD1b. This case further supports the
association between GSD1b and autoimmune diseases.
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Glycogen storage disease type 1b (GSD1b; OMIM 232220)
is an inherited metabolic defect due to mutations of
the SLC37A4 gene that encodes a microsomal glucose-6-
phosphate transporter (G6PT) [1]. Decreased transport of
glucose-6-phosphate (G6P) across the microsomal mem-
brane causes inability of G6P to come in contact with the
catalytic unit of glucose-6-phosphatase (G6Pase-alpha),
insufficient conversion of G6P into glucose and phos-
phate, and defective glycogenolysis and gluconeogenesis
[2,3]. The biochemical defect of GSD1b results in a
phenotype characterized by hepatomegaly and failure
to thrive, which is similar to that of other liver glyco-
genoses, and in typical biochemical abnormalities (fasting
hypoglycemia, hyperlacticacidemia, hyperlipidemia, hyper-
uricemia). The treatment of GSD1b is mainly based on a
dietary regimen with frequent meals, nocturnal gastric
drip feeding and use of uncooked starches with low
glycemic index.* Correspondence: daniela.melis@unina.it
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GSD1b is associated with neutropenia and/or neutrophil
dysfunction that cause increased susceptibility to recurrent
bacterial infections, aphthous stomatitis, and inflammatory
bowel disease (IBD) [4,5].
Although these manifestations are highly debilitating
and impact significantly on patients’ quality of life, their
pathophysiology is still poorly characterized. Granulocyte-
Colony Stimulating factor (G-CSF) is commonly used, in
addition to the standard dietary treatment, for the man-
agement of neutrophil abnormalities in GSD1b patients
and is effective in decreasing the frequency of infections
[1,4-7].
These abnormalities of neutrophil count and function
have been claimed to be a predisposing factor to auto-
immune diseases [8,9]. Reports have been published in
the recent literature on the association between GSD1b
and IBD [4], autoimmune thyroiditis [10], growth hor-
mone (GH) deficiency [11], and autoimmune myastenia
gravis [12]. The possible role of autoimmunity in GH
deficiency has also been reported [13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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showed several manifestations of autoimmunity includ-
ing IBD, autoimmune thyroiditis and autoimmune GH
deficiency.
Case presentation
GDN, a male, was the first child of third cousin parents.
He was delivered by caesarean section. In the neonatal
period he presented with hypoglycemia, seizures, hyper-
bilirubinemia (16 mg/dL), and hemolytic disease due to
AB0 incompatibility.
At the age of three months he was first referred to
Genetic Clinic Unit because of fasting hypoglycemia with
seizures, liver enlargement, recurrent infections, and can-
didiasis. The diagnosis of GSD1b was based on the clinical
presentation, on the typical biochemical profile with lactic
acidosis, dyslipidemia, and hyperuricemia, and on the
assay of glucose-6-phosphatase in fresh and frozen liver
samples. When the molecular diagnosis of the disease
became available, the diagnosis was confirmed by the
mutational analysis of the SLC37A4 gene, showing homo-
zygosity for the mutation c.1211-1212delCT.
A diet based on frequent meals and nocturnal gastric
drip-feeding was started and the patient was included in
a follow-up program at our Department. Biochemical
and growth parameters improved after the start of
dietary treatment.
During the follow-up, however, GDN presented with
many of the known complications of GSD1b.
At the age of 6 months neutropenia was detected. The
median neutrophil count, over a 5-year follow-up period,
was 1160/mm3, ranging between 230 and 4523. A ther-
apy with G-CSF was started at the age of 6 months with
a dose of 3–5 μg/kg/day.
Recurrent respiratory and gastro-intestinal infections
and splenomegaly were also recorded.
When he was 8 years old, glomerular hyperfiltration
and microalbuminuria were detected on routine biochem-
ical evaluations and treatment with ACE-inhibitors was
started to prevent further progression of renal disease.
In addition to the known complications of GSD1b, the
patient presented with disorders suggesting autoimmunity.
At the age of 7 years, given the presence of stomatitis
aphthosa and perianal ulcers, an ileocolonoscopy was
performed showing signs of non-specific chronic inflam-
mation. A scintigraphy with 99mTechnetium-labeled au-
tologous white cell (Tc-WCS) showed moderate to high
degree neutrophil chemiotaxis at the ileocaecal junction.
A terminal ileum ultrasonography showed increased
bowel wall thickness. The treatment of the intestinal
involvement was based on the use of an elemental diet
and periodic administration of antibiotics.
Biochemical evidence of autoimmune thyroiditis with
subclinical hypothyroidism was observed at the age of12 years. The diagnosis was based on repeated increased
basal TSH levels and thyroid auto-antibodies (Table 1),
with abnormal echogenicity of the parenchyma on a thy-
roid ultrasound scan. During the follow-up, TSH levels
were always below 10 μU/ml and thus he never started
a replacement therapy with L-thyroxine [14,15]. At that
time, a complete panel of serum autoantibodies was
assayed showing increased antibodies against ANA,
Anti-C1Q, Anti-C3d (Table 1).
When he was 14-years-old, reduced height velocity
(Figure 1), short stature, and retarded bone maturation
(corresponding to 12 years) were observed. At that time
pubertal stage was G2P2, TSH was 5.6 μU/ml with
normal fT4 1.2 ng/dl (normal values 0.7-1.7). A GH-RH
plus arginine test was performed, showing reduced
GH response (peak 7,8 ng/dl) (Figure 2). High titer of
anti-pituitary antibodies recognizing growth hormone-
producing cells (>1:8) were also detected, indicating an
autoimmune growth hormone deficiency. A pituitary Mag-
netic Resonance Imaging was normal, showing a normal
gland architecture. The adrenal gland function was also
evaluated, showing normal basal hormone levels and nor-
mal response to a dynamic low dose ACTH test (Table 1).
At the age of 16 years he also showed delayed pubertal
development; also in this case no treatment was started.
At that time, considering the increased number of infec-
tions and their seriousness and the appearance of skin
pigmentation, adrenal function was re-evaluated, show-
ing basal ACTH 15 ng/ml and basal cortisol 54 ng/ml.
A dynamic low dose ACTH test was also performed
showing a significant increase in cortisol levels (cortisol
T0 51.1 ng/ml, T30 221 ng/ml, T60 229 ng/ml, T90
260 ng/ml), thus suggesting a normal functioning of the
adrenal gland and only a slight pituitary dysfunction.
Conclusions
We report on a patient presenting with different mani-
festations related to altered immune response, such as
increased susceptibility to bacterial infections, autoim-
mune thyroiditis and autoimmune GH deficiency. In
GSD1b, neutropenia and impaired neutrophil function
represent the primum movens of the reduced response to
infection.
The occurrence of autoimmune disorders has been
reported in GSD1b only in the recent years and little is
known about its pathophysiology. Different hypotheses
may be considered to explain the presence of autoim-
mune disorders in GSD1b patients.
Firstly it is known that autoimmunity may be related
to the defective function of neutrophils. In fact, there are
several disorders in which abnormal function of neutro-
phil is associated with autoimmunity. For example car-
rier mothers of children with chronic granulomatous
disease, an X-linked defect of phagocytosis, often develop
Table 1 Endocrine profile at 14 years
Results Reference values
Thyroid TSH (μU/ml) 5.6 0.5–4.5
FT3 (pg/ml) 3.5 1.6–3.4
FT4 (ng/dl) 1.2 0.7–1.7
Anti-TPO (UI/ml) 57 0–40
Anti-thyreoglobulin (UI/ml) 121 0–40
Growth hormone & pituitary Basal GH (ug/l) 0.04 0.2–5
IGF-I (ug/l) 53.9 100–500
Anti-pituitary antibodies 1:8 0
Adrenals Basal ACTH (ng/ml) 17.6 10–130
Basal cortisol (ng/ml) 120 50–200
ACTH test




Anti-adrenal gland antibodies Absent Absent
Anti-ACTH antibodies Absent Absent
Auto-antibody profile ANA (U/ml) 3.1 0–1
Ds-DNA (UI/ml) 0 0–5
ANCA (U/ml) 0 0–5
ASCA (U/ml) 0 <20
Cardiolipin (PLU/ml) 0 <10
Phospholipid (U/ml) 0 <10
Acetylcholine receptor (nmol/l) 0 0–0.25
Anti-C1Q (U/ml) 140 1–40
Anti-C3d (U/ml) 120 0–24
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body deficiencies, such as Wiskott-Aldrich syndrome, are
associated with an increased risk for juvenile rheumatoid
arthritis and autoimmune hemolytic anemia [9].
Secondly, immunologic defects may determine a failure
to exclude microbial antigens, thus resulting in chronic
immunologic activation, with the rising of autoimmune
manifestations [16]. In GSD1b patients, recurrent infec-
tions may lead to increased expression of MHC antigens
or trigger the immune response through molecular mim-
icry and cross-reactivity between endogenous and micro-
bial peptides.
In addition, it might be hypothesized that, in GSD1b
patients, failure of neutrophils to achieve intracellular
killing of bacteria may result in induction of lymphocyte
THl-type proliferation as a compensatory mechanism [16].
In our patient we observed only minor endocrine auto-
immune manifestations, involving pituitary gland, thyroid
and adrenal gland. Considering that TSH levels werealways below 10 μU/ml and basal ACTH and cortisol
were in the low reference range, he never started a
specific therapy. As far as GH deficiency is concerned
no replacement therapy was started, considering that
rhGH is known to stimulate gluconeogenesis and to in-
crease fasting insulin levels and insulin-resistance [17,18]
thus interfering with glucose metabolism and possibly
worsening metabolic imbalance in GSD1. In addition it is
known the promoting effect of GH on the growth of liver
cell adenomas [19], a known long-term complication in
GSD1. Therefore, we decided to monitor auxological pa-
rameters before beginning therapy with rhGH, consider-
ing its potential dangerousness.
Although no hormone replacement therapy was started
in our patient, it is difficult to predict whether in other
patients these manifestations may contribute to the clinical
picture of the diseases and impact on patients’ quality of
life. It has been recently reported that patients with GSD1b
are more likely to experience a poor quality of life [20].
Figure 1 Patient’s growth pattern. Height velocity deceleration was observed when the patient was 15 years old. The arrow indicates the time
GH-RH plus arginine dynamic test was performed. Final height was below mid-parental height.
Figure 2 Graphic representation of GH-RH plus arginine dynamic test demonstrating GH deficiency in the patient. The patient is
represented by ▲.
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immunodeficiency and autoimmunity, we suggest moni-
toring GSD1b patients for autoimmune disorders.
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